Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 16

recruiting
3 987
countries
28
conditions
2 109

334 trials match your criteria

Primary immunodeficiency syndrome

Not recruiting

Study on the Effects of TAK-881 and Hyaluronidase in Adults with Primary Immunodeficiency Diseases

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin

Primary immunodeficiency syndrome

Not recruiting

Study on Long-term Safety of TAK-881 (Human Normal Immunoglobulin, Hyaluronidase) for Patients with Primary Immunodeficiency Diseases

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin

Dermatitis atopic

Not recruiting

Study of Baricitinib for Children and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Baricitinib

Dermatitis atopic

Not recruiting

Study on Long-Term Safety and Effectiveness of Abrocitinib for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abrocitinib

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab

Dermatitis atopic

Not recruiting

Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab

Dermatitis atopic+1

Not recruiting

Study of Lebrikizumab and Topical Corticosteroids for Children and Teens with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Glucocorticoids

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Cabozantinib

Food allergy

Not recruiting

Study of DBV712 skin patch safety in children aged 1-3 years with peanut allergy

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Water For Injection

Alopecia areata

Not recruiting

Study of ritlecitinib for treating severe alopecia areata in children aged 6 to under 12 years

Investigational
Countries:SpainSpain
  • Participants:0–17 years

PIK3CA related overgrowth spectrum

Not recruiting

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib

Duchenne muscular dystrophy

Not recruiting

Study of BMN 351 given by intravenous infusion to evaluate safety and tolerability in patients with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.